Adverse drug events in children: The US food and drug administration perspective

Current Therapeutic Research - Clinical and Experimental

Volumn 62, Issue 10, 2001, Pages 711-723

  Rodriguez, William ^a,b   Roberts, Rosemary ^a   Murphy, Dianne ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b HFD 104 ^*  (United States)

Author keywords

Adverse events; Exclusivity initiative; Off label use; Pediatric drugs

Indexed keywords

ACETYLSALICYLIC ACID; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BENZYL ALCOHOL; CEFTRIAXONE; CHLORAMPHENICOL; DERMATOLOGICAL AGENT; DOXORUBICIN; ETODOLAC; FENTANYL; FLUTICASONE PROPIONATE; FLUVOXAMINE; GABAPENTIN; HEXACHLOROPHENE; ISOFLURANE; ISOTRETINOIN; LORATADINE; MIDAZOLAM; NITRIC OXIDE; PANCRELIPASE; PARACETAMOL; PROPOFOL; PSYCHOTROPIC AGENT; RETINOID; SPIRONOLACTONE; STEROID; TETRACYCLINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VERAPAMIL;

CARDIOTOXICITY; CHILD; CHILD DEVELOPMENT; CHILDHOOD DISEASE; DRUG APPROVAL; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG LABELING; DRUG MONITORING; DRUG OVERDOSE; FOOD AND DRUG ADMINISTRATION; HUMAN; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW;

EID: 0035196615     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(01)80078-3     Document Type: Article

References (43)

1. Therapeutic orphans
2. Milestones in US Food and drug law history-FDA backgrounder
3. Medication errors and adverse drug events in pediatric inpatients
4. Critical periods of vulnerabilities for the developing nervous systems: Evidence from human and animal models
5. Mechanisms of drug absorption and their development
6. Structural aspects of prenatal and postnatal development and growth of the lung
7. Idiosyncratic drug reactions: The reactive metabolite syndromes
8. Clinical assessment of drug-induced disease
9. Phenobarbital for febrile seizures - Effects on intelligence and on seizure recurrence
10. Drugs and their treatment of psychiatric disorders
11. Therapeutic doses of theophylline exert proconvulsant effects in developing mice
12. Antimicrobial agents
13. Benzyl alcohol toxicity: Impact on mortality and intraventricular hemorrhage among very low birth weight infants
14. Alcohols and glycols. Benzyl alcohol clinical presentation
15. Chloramphenicol and tetracycline
16. Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout
17. Two-compartment gentamicin pharmacokinetics in premature neonates: A comparison to adults with decreased glomerular filtration rates
18. Renal toxicity of aminoglycosides in the neonatal period
19. The developmental toxicity of three antimicrobial agents observed only in nonroutine animal studies
20. Hexachlorophene
21. Reye's syndrome in the United States from 1981 through 1987
22. Systematic toxicology. Antiarrhythmics drug class IV calcium channel blockers
23. Ontogenetic differences in cardiac sensitivity to verapamil in rats
24. Daunorubicin hydrochloride
25. Systemic toxicology. The antihypertensive drugs
26. Over-the-counter products and drug interactions: The retinoids
27. Attention deficit hyperactivity disorder
28. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system
29. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system, by William DuMouchel
30. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system, by William DuMouchel
31. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system, by William DuMouchel
32. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system, by William DuMouchel
33. The application of Bayesian data mining and graphic visualization tools to screen FDA's spontaneous reporting system database
34. Empirical Bayes screening for multi-item associations
35. Analysis and risk assessment of hematological data from clinical trials
36. Discussion: A report on the activities of the adverse events working groups: Focus on improving the detection of rare but serious adverse events
37. Some US Food and Drug Administration perspectives on data mining for pediatric safety assessment
38. Valproic acid hepatic fatalities: A retrospective review